Literature DB >> 10081613

Partitioning lung and plasma proteins: circulating surfactant proteins as biomarkers of alveolocapillary permeability.

I R Doyle1, T E Nicholas, A D Bersten.   

Abstract

1. The alveolocapillary membrane faces an extraordinary task in partitioning the plasma and lung hypophase proteins, with a surface area approximately 50-fold that of the body and only 0.1-0.2 micron thick. 2. Lung permeability is compromised under a variety of circumstances and the delineation between physiological and pathological changes in permeability is not always clear. Although the tight junctions of the epithelium, rather than the endothelium, are regarded as the major barrier to fluid and protein flux, it is becoming apparent that the permeability of both are dynamically regulated. 3. Whereas increased permeability and the flux of plasma proteins into the alveolar compartment has dire consequences, fortuitously the flux of surfactant proteins from the airspaces into the circulation may provide a sensitive means of non-invasively monitoring the lung, with important implications for treatment modalities. 4. Surfactant proteins are unique in that they are present in the alveolar hypophase in high concentrations. They diffuse down their vast concentration gradients (approximately 1:1500-7000) into the circulation in a manner that reflects lung function and injury score. Surfactant proteins vary markedly in size (approximately 20-650 kDa) and changes in the relative amounts appear particularly diagnostic with regard to disease severity. Alveolar levels of surfactant proteins remain remarkably constant despite respiratory disease and, unlike the flux of plasma proteins into the alveolus, which may reach equilibrium in acute lung injury, the flux of surfactant proteins is unidirectional because of the concentration gradient and because they are rapidly cleared from the circulation. 5. Ultimately, the diagnostic usefulness of surfactant proteins as markers of alveolocapillary permeability will demand a sound understanding of their kinetics through the vascular compartment.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10081613     DOI: 10.1046/j.1440-1681.1999.03015.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  6 in total

1.  Interactions between smoking, pulmonary surfactant protein B, and atherosclerosis in the general population: the Dallas Heart Study.

Authors:  Ann B Nguyen; Anand Rohatgi; Christine K Garcia; Colby R Ayers; Sandeep R Das; Susan G Lakoski; Jarett D Berry; Amit Khera; Darren K McGuire; James A de Lemos
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-08-04       Impact factor: 8.311

2.  Contribution of Human Lung Parenchyma and Leukocyte Influx to Oxidative Stress and Immune System-Mediated Pathology following Nipah Virus Infection.

Authors:  Olivier Escaffre; Tais B Saito; Terry L Juelich; Tetsuro Ikegami; Jennifer K Smith; David D Perez; Colm Atkins; Corri B Levine; Matthew B Huante; Rebecca J Nusbaum; Janice J Endsley; Alexander N Freiberg; Barry Rockx
Journal:  J Virol       Date:  2017-07-12       Impact factor: 5.103

Review 3.  Monitoring alveolar epithelial function in acute lung injury.

Authors:  R H Hastings
Journal:  J Clin Monit Comput       Date:  2000       Impact factor: 2.502

4.  Anti-KC autoantibody:KC complexes cause severe lung inflammation in mice via IgG receptors.

Authors:  Agnieszka Krupa; Maria J Walencka; Vivek Shrivastava; Tameka Loyd; Rafal Fudala; Charles W Frevert; Thomas R Martin; Anna K Kurdowska
Journal:  Am J Respir Cell Mol Biol       Date:  2007-06-21       Impact factor: 6.914

5.  Plasma surfactant protein-B is elevated in infants with respiratory syncytial virus-induced bronchiolitis.

Authors:  S Z Wang; I R Doyle; T E Nicholas; K D Forsyth
Journal:  Pediatr Res       Date:  1999-12       Impact factor: 3.756

6.  Valuable Serum Markers in Pulmonary Alveolar Proteinosis.

Authors:  Shenyun Shi; Lulu Chen; Xiaohua Qiu; Qi Zhao; Yonglong Xiao; Xin Yan
Journal:  Dis Markers       Date:  2019-11-11       Impact factor: 3.434

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.